<DOC>
	<DOCNO>NCT00636961</DOCNO>
	<brief_summary>This study evaluate effect QAB149 dynamic static hyperinflation , breathlessness , health status COPD patient</brief_summary>
	<brief_title>An Exploratory Study , Assess Effect Repeat-dose Inhaled Indacaterol Maleate ( 300 μg ) Dynamic Static Lung Hyperinflation , Subjective Breathlessness Health Status Patients With Chronic Obstructive Pulmonary Disease ( COPD )</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Dyspnea</mesh_term>
	<mesh_term>Maleic acid</mesh_term>
	<criteria>Male female subject , 40 80 year age , document diagnosis mild , moderate severe chronic obstructive pulmonary disease ( COPD ) accord Global Initiative Chronic Obstructive Lung Disease ( GOLD ) criteria &gt; 20pack year history smoking , postbronchodilator 40 % ≤ FEV1 ≤ 80 % predict normal postbronchodilator FEV1/FVC &lt; 70 % sign informed consent form ( ICF ) prior initiation studyrelated procedure ( Post bronchodilator refers 30 minute inhalation 400 µg salbutamol ) Subjects demonstrate plethysmographic functional residual capacity &gt; 120 % predict normal No COPD exacerbation within 6 week prior dose , concomitant lung disease asthma , requirement long term oxygen treatment history lung reduction surgery . No medical condition would interfere performance spirometry clinical exercise test . Any medical condition opinion investigator may cause patient unsuitable completion study place patient potential risk participate study e.g . uncontrolled hypertension unstable ischemic heart disease Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>July 2011</verification_date>
	<keyword>COPD , Indacaterol Maleate , Exercise test</keyword>
</DOC>